Hypothesis

Mitochondria‑associated membrane (MAM) NAD+ pools, generated by a mitochondrially targeted NAMPT isoform, determine the stability of respiratory supercomplexes in aged cardiomyocytes, independent of PGC-1α‑driven biogenesis.

Mechanistic rationale

• Compartmentalized NAD+/NADH ratios regulate sirtuin activity; SIRT3 deacetylates subunits of Complex I and IV, promoting their incorporation into respirasomes.
• Recent work shows that NAD+ supplementation fails to restore cardiac respiration because cytosolic NAD+ does not equilibrate with the MAM microdomain where SIRT3 resides (2).
• PGC‑1α activation increases mitochondrial content but does not guarantee that newly formed organelles acquire the NAD+‑rich MAM environment needed for SIRT3‑mediated stabilization of supercomplexes (1).
• We propose that boosting NAD+ synthesis specifically at MAMs will raise local NAD+/NADH, activate SIRT3, reduce aberrant acetylation of Complex I NDUFS2 and IV COX4I1, thereby enhancing supercomplex assembly and lowering proton leak.

Testable predictions

1. Cardiac‑specific expression of a MAM‑targeted NAMPT (MAM‑NAMPT) in old mice will increase MAM NAD+/NADH ratio by ≥2‑fold without altering total cytosolic NAD+ (3).
2. This manipulation will restore Complex I‑IV supercomplex abundance to youthful levels, as measured by BN‑PAGE, despite unchanged PGC-1α expression and mitochondrial DNA copy number.
3. Consequently, maximal oxygen consumption rate (OCR) and ATP production will rise, while mitochondrial ROS and proton leak (measured by Seahorse XF) will fall, surpassing the effects of PGC-1α overexpression alone.
4. Pharmacological inhibition of SIRT3 will abolish the functional improvements, confirming the dependence on deacetylation activity.

Experimental approach

• Generate AAV9 vectors carrying MAM‑NAMPT (NAMPT fused to an ER‑mitochondria tether sequence) and a control AAV9‑GFP.
• Inject into 24‑month‑old C57BL/6J mice; assess after 4 weeks.
• Isolate cardiac mitochondria; quantify NAD+/NADH in cytosolic, mitochondrial matrix, and MAM fractions using enzymatic cycling assays.
• Evaluate supercomplex assembly by blue‑native PAGE followed by immunoblot for NDUFA9 (Complex I) and COXII (Complex IV).
• Measure OCR, ATP‑linked respiration, leak, and ROS with Seahorse XF Analyzer.
• Include groups: PGC‑1α overexpression via AAV9, combined MAM‑NAMPT + PGC‑1α, and SIRT3 inhibitor (3‑TY) treatment.

Implications

If validated, the hypothesis shifts the focus from global NAD+ repletion to organelle‑specific NAD+ microdomains as a decisive factor for respiratory efficiency. It suggests that therapeutic strategies must couple biogenesis inducers with targeted NAD+ biosynthesis to achieve true metabolic rejuvenation in aging heart.